Frequency Therapeutics to Participate in Upcoming March 2022 Investor Conferences
28 February 2022 - 11:30PM
Business Wire
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage
regenerative medicine company focused on developing therapeutics to
activate a person’s innate regenerative potential to restore
function, today announced that Chief Executive Officer David L.
Lucchino will participate in two upcoming investor conferences:
- Cowen 42nd Annual Health Care Conference: Corporate
Panel Discussion - Auditory and Ophthalmology, March 7, 2022, 2:10
p.m. to 3:10 p.m. EST
- Oppenheimer 32nd Annual Healthcare Conference: Company
Overview Presentation, Wednesday, March 16, 2022, 3:20 p.m. to 3:50
p.m. EST
A live webcast of both the panel and presentation can be
accessed on the investors section of Frequency’s website,
investors.frequencytx.com. A replay of each will be posted on the
Frequency website following the events.
About Frequency Therapeutics
Frequency Therapeutics is leading a new category in regenerative
medicine that aims to restore function – first in hearing loss and
then in multiple sclerosis (MS) – by developing therapeutics that
activate a person’s innate regenerative potential within the body
through the activation of progenitor cells to restore lost
function. Frequency’s hearing research focuses on cochlear
restoration and auditory repair, and its lead asset, FX-322, is a
small-molecule product candidate that is the first to show
statistically significant and clinically meaningful hearing
improvements in clinical trials for SNHL. Frequency is also
following early restorative signals in MS to develop medicines with
the same underlying regenerative science being brought to hearing
loss.
Headquartered in Lexington, Mass., Frequency has an ex-U.S.
license and collaboration agreement with Astellas Pharma Inc. for
FX-322, as well as additional collaboration and licensing
agreements with academic and nonprofit research organizations
including Massachusetts Eye and Ear, Mass General Brigham, the
Massachusetts Institute of Technology, the Scripps Research
Institute and Cambridge Enterprises Limited. For more information,
visit www.frequencytx.com and follow Frequency on Twitter
@Frequencytx.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220228005115/en/
Investors: Carlo Tanzi, Ph.D. Kendall Investor Relations
ctanzi@kendallir.com 617-914-0008
Media: Suzanne Day Frequency Therapeutics
sday@frequencytx.com 781-496-2211
Frequency Therapeutics (NASDAQ:FREQ)
Historical Stock Chart
From Apr 2024 to May 2024
Frequency Therapeutics (NASDAQ:FREQ)
Historical Stock Chart
From May 2023 to May 2024